This is the first data to show the entry and replication of an oncolytic virus specific for a clinically relevent cellular target protein.

In-vivo tumor regression is seen when CD20 positive tumor is treated with modified MV.

The next goal is to further engineer the virus to eliminate binding to CD46 and SLAM, its natural targets.

Clinical/Scientific Implications

The CD20 antigen is important for the treatment of NHL. This study illustrates one other mechanism by which the CD20 antigen can help target cytotoxic mechanisms to tumor cells. Further laboratory study to eliminate unwanted binding to the native MV target epitopes and to ensure safety is warranted prior to considering human testing.

Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Ortho Biotech.